HONG KONG – China's contract drugmaking giant, Wuxi Biologics Inc., of Wuxi city, is actively expanding its global footprint, announcing plans to work with its Canadian partner on a brain cancer drug and opening its 10th global manufacturing facility in Singapore.
HONG KONG – Newly launched Chinese biotech Brii Biosciences is looking to use an experienced management team, partnerships and $260 million in initial funding to bring innovative medicines to its home market faster. Its initial focus will be infectious diseases.
HONG KONG – South Korean bioinformatics company Syntekabio Inc. pocketed $11.2 million in a series B financing to advance two of it core platforms in bioinformatics and AI-driven drug discovery to speed up drug development process.
HONG KONG – Denmark's Novo Nordisk A/S has teamed up with Singapore's Duke-NUS Medical School to provide funding for the next three to five years for stem cell-based research aimed at growing heart muscle and retinal cells to treat heart failure and vision loss.
HONG KONG – China's Chia Tai Tianqing Pharmaceutical Holdings Co. Ltd. gained marketing approval for its first innovative treatment for advanced non-small-cell lung cancer (NSCLC), which has the potential of becoming a standard third-line treatment for the disease.
HONG KONG – Chugai Pharmaceutical Co. Ltd., of Tokyo, said its Alecensa (alectinib), an anaplastic lymphoma kinase (ALK) inhibitor, gained expanded approved as a first-line treatment for ALK-positive non-small-cell lung cancer (NSCLC) in Taiwan.
HONG KONG – South Korea's Samsung Biologics Co. Ltd., one of the world's biggest biologic drug manufacturers, has seen its stock price fall 20 percent this month as allegations of accounting fraud remain in play after a year of investigation.
HONG KONG – South Korea's Samsung Biologics Co. Ltd., one of the world's biggest biologic drug manufacturers, has seen its stock price fall 20 percent this month as allegations of accounting fraud remain in play after a year of investigation.
HONG KONG – Chugai Pharmaceutical Co. Ltd., of Tokyo, said its Alecensa (alectinib), an anaplastic lymphoma kinase (ALK) inhibitor, gained expanded approved as a first-line treatment for ALK-positive non-small-cell lung cancer (NSCLC) in Taiwan.
HONG KONG – China's Chia Tai Tianqing Pharmaceutical Holdings Co. Ltd. gained marketing approval for its first innovative treatment for advanced non-small-cell lung cancer (NSCLC), which has the potential of becoming a standard third-line treatment for the disease.
